U.S. Markets closed

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

Zacks Equity Research
Celanese (CE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals (ANIP) closed at $69.66 in the latest trading session, marking a -0.49% move from the prior day. This move lagged the S&P 500's daily loss of 0.04%. At the same time, the Dow lost 0.51%, and the tech-heavy Nasdaq gained 0.21%.

Coming into today, shares of the drugmaker had gained 5.44% in the past month. In that same time, the Medical sector lost 5.37%, while the S&P 500 gained 4.65%.

Wall Street will be looking for positivity from ANIP as it approaches its next earnings report date. The company is expected to report EPS of $1.03, down 21.97% from the prior-year quarter.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.97 per share and revenue of $248 million. These totals would mark changes of +17.75% and +23.03%, respectively, from last year.

It is also important to note the recent changes to analyst estimates for ANIP. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ANIP is holding a Zacks Rank of #1 (Strong Buy) right now.

Digging into valuation, ANIP currently has a Forward P/E ratio of 11.73. This represents a discount compared to its industry's average Forward P/E of 20.82.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 55, which puts it in the top 22% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.